In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Real world discontinuation among early users of apixaban, dabigatran, rivaroxaban or warfarin among atrial fibrillation patients newly initiated on anticoagulation therapy: tell of first 200 days

Session Novel anticoagulants: trials, cost, real life use

Speaker Hemant Phatak

Event : ESC Congress 2014

  • Topic : arrhythmias and device therapy
  • Sub-topic : Atrial Fibrillation
  • Session type : Abstract Session

Authors : X Pan (Princeton, NJ,US), S Kachroo (Princeton, NJ,US), X Liu (New York,US), H Kawabata (Princeton, NJ,US), H Phatak (Princeton, NJ,US)

X. Pan1 , S. Kachroo1 , X. Liu2 , H. Kawabata1 , H. Phatak1 , 1Bristol Myers Squibb - Princeton, NJ - United States of America , 2Pfizer, Inc. - New York - United States of America ,

European Heart Journal ( 2014 ) 35 ( Abstract Supplement ), 897

Purpose: This study evaluated discontinuation of apixaban, dabigatran, and rivaroxaban in the first 200 days after launch in patients with atrial fibrillation (AF) in the US real-world clinical practice setting.

Methods: A retrospective cohort study was conducted using MarketScan® including the Earlyview data. AF Patients >18 years (ICD-9 code 427.31 or 472.32) with one year of baseline period were included if they were newly prescribed the novel oral anticoagulants (NOACs) during the first 200 days after their availability in the US market, or newly prescribed warfarin after apixaban launch. Discontinuation was defined as lack of subsequent prescription of the index drug within 30 days after the last supply day of the last prescription. Cox proportional hazards model was used to compute hazard ratio (HR) of discontinuation, adjusting for potential confounders and other important patient characteristics.

Results: Among 17,356 eligible patients, 841 (4.85%) were initiated with apixaban, 5,805 (33.45%) with dabigatran, 2,125 (12.24%) with rivaroxaban and 8,585 (49.46%) with warfarin. The mean age of apixaban, dabigatran, rivaroxaban and warfarin patients were 70.3±12.0 years, 69.1±12.4 years, 69.2±12.1 years and 71.9±12.3 respectively. After adjusting baseline patient characteristics, apixaban was significantly less likely to discontinue versus rivaroxaban (HR: 0.60; CI: 0.48, 0.74) and warfarin (HR: 0.55, CI: 0.45 - 0.67) (Figure).

Conclusion: The risk of discontinuation was lower for apixaban versus rivaroxaban or warfarin among newly anticoagulated AF patients. These early findings with relatively short follow-up should be confirmed in future with larger sample size and longer term follow-up.

Figure 1

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are